Login to Your Account



Morphosys, GSK Ink $586M Pact for MOR103 in RA, MS

By Cormac Sheridan
Staff Writer

Wednesday, June 5, 2013
German biotech received a badly needed boost this week with the news that GlaxoSmithKline plc was in-licensing MOR103, an antibody in clinical development in rheumatoid arthritis (RA) and multiple sclerosis (MS) at veteran antibody developer Morphosys AG, in return for an up-front payment of €22.5 million (US$29 million), plus another potential €423 million in milestones linked to its progress through clinical development, regulatory approval and sales.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription